Understanding the Role of Akt and HER2/neu in Breast Cancer Among African-American and Latina Women
Author Information
Author(s): Wu Yanyuan, Hezla Mohamed, Ram Chillar, Ishrat Ali, Clayton Sheila, Slamon Dennis, Vadgama Jaydutt V
Primary Institution: Charles R. Drew University of Medicine and Science
Hypothesis
A subgroup of patients with HER2/neu-overexpressing breast cancer will also demonstrate an increase in activated Akt in their tumors, leading to resistance to chemotherapy and consequently shorter disease-free survival (DFS) and overall survival (OS).
Conclusion
The overexpression of pAkt may be a powerful prognostic marker for predicting disease-free survival and overall survival of breast cancer patients.
Supporting Evidence
- Patients with low pAkt and HER2-negative tumors had the best disease-free survival.
- Higher pAkt levels were significantly associated with HER2/neu-positive and lymph node-positive breast tumors.
- Overexpression of pAkt was linked to a decrease in 5-year disease-free survival.
- More than 70% of patients with HER2/neu-positive tumors had overexpression of pAkt.
Takeaway
This study found that women with certain types of breast cancer have a higher chance of not surviving as long, especially if their tumors have high levels of a protein called pAkt.
Methodology
Retrospective analysis of tumor tissue samples from 234 African-American and Latina patients, with 141 samples analyzed for pAkt expression using immunohistochemistry.
Potential Biases
Potential bias due to the retrospective nature of the study and the specific demographic focus.
Limitations
The study was limited to African-American and Latina women, excluding Caucasian patients, which may affect the generalizability of the findings.
Participant Demographics
Participants were primarily African-American (51.1%) and Latina (48.9%) women with breast cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website